[go: up one dir, main page]

WO2025010308A3 - Mdma enantiomer compositions and methods for modulating aggression response - Google Patents

Mdma enantiomer compositions and methods for modulating aggression response Download PDF

Info

Publication number
WO2025010308A3
WO2025010308A3 PCT/US2024/036639 US2024036639W WO2025010308A3 WO 2025010308 A3 WO2025010308 A3 WO 2025010308A3 US 2024036639 W US2024036639 W US 2024036639W WO 2025010308 A3 WO2025010308 A3 WO 2025010308A3
Authority
WO
WIPO (PCT)
Prior art keywords
mdma
aggression
modulating
methods
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/036639
Other languages
French (fr)
Other versions
WO2025010308A2 (en
Inventor
Glenn Short
Carrie BOWEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Empathbio Inc
Original Assignee
Empathbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Empathbio Inc filed Critical Empathbio Inc
Publication of WO2025010308A2 publication Critical patent/WO2025010308A2/en
Publication of WO2025010308A3 publication Critical patent/WO2025010308A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed are pharmaceutical compositions and formulations of enantiomerically enriched or pure 3,4-methylenedioxymethamphetamine (MDMA) and methods for modulating aggression response behaviors that may be associated with a disorder and/or disease.
PCT/US2024/036639 2023-07-03 2024-07-03 Mdma enantiomer compositions and methods for modulating aggression response Pending WO2025010308A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363524735P 2023-07-03 2023-07-03
US63/524,735 2023-07-03

Publications (2)

Publication Number Publication Date
WO2025010308A2 WO2025010308A2 (en) 2025-01-09
WO2025010308A3 true WO2025010308A3 (en) 2025-04-17

Family

ID=94172268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/036639 Pending WO2025010308A2 (en) 2023-07-03 2024-07-03 Mdma enantiomer compositions and methods for modulating aggression response

Country Status (1)

Country Link
WO (1) WO2025010308A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210346341A1 (en) * 2020-05-05 2021-11-11 Universitätsspital Basel Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin, or other psychedelics
WO2022069690A2 (en) * 2020-10-02 2022-04-07 Cybin Irl Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
US20220354822A1 (en) * 2021-05-05 2022-11-10 Mind Medicine, Inc. Mdma enantiomers
WO2023283386A2 (en) * 2021-07-07 2023-01-12 Arcadia Medicine, Inc. Safer psychoactive compositions
WO2023056102A1 (en) * 2021-10-01 2023-04-06 ATAI Life Sciences AG Novel prodrugs of mdma, mda, and derivatives thereof
US20230113351A1 (en) * 2019-01-30 2023-04-13 Diamond Therapeutics Inc. Compositions and methods for managing disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230113351A1 (en) * 2019-01-30 2023-04-13 Diamond Therapeutics Inc. Compositions and methods for managing disorders
US20210346341A1 (en) * 2020-05-05 2021-11-11 Universitätsspital Basel Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin, or other psychedelics
WO2022069690A2 (en) * 2020-10-02 2022-04-07 Cybin Irl Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
US20220354822A1 (en) * 2021-05-05 2022-11-10 Mind Medicine, Inc. Mdma enantiomers
WO2023283386A2 (en) * 2021-07-07 2023-01-12 Arcadia Medicine, Inc. Safer psychoactive compositions
WO2023056102A1 (en) * 2021-10-01 2023-04-06 ATAI Life Sciences AG Novel prodrugs of mdma, mda, and derivatives thereof

Also Published As

Publication number Publication date
WO2025010308A2 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
WO2025010308A3 (en) Mdma enantiomer compositions and methods for modulating aggression response
HUP9702424A2 (en) Melt-extruded solid active ingredient preparations
EP4524133A3 (en) Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
EP0776660A3 (en) Long-lasting release nifedipine preparation
AR034691A1 (en) PHARMACEUTICAL COMPOSITIONS OF ORAL ADMINISTRATION, CONTAINING A GASTROINTESTINAL LIPASE INHIBITOR, THE MASTICABLE TABLET AND THE COOKIE THAT INCLUDES THEM
HRP20130715T1 (en) Oral dosage form safeguarded against abuse containing (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
MX2023001744A (en) Crystalline forms of cftr modulators.
PL1931316T5 (en) Controlled release pharmaceutical compositions for acid labile drugs
IL314009B1 (en) PARP1 inhibitors and their uses
WO2019232433A3 (en) Methods of using splicing modulators
AU2020210930B2 (en) GPR35 modulators
MX2023012835A (en) Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor.
WO2022106902A8 (en) Benzenesulfonamide derivatives and uses thereof
WO2020172324A8 (en) Nurr1 receptor modulators
WO2022234337A3 (en) Crystalline carbazole derivative
WO2017139331A8 (en) Pharmaceutical bead formulations comprising dimethyl fumarate
DE69707964T2 (en) Medicinal product containing multiantioxidant
WO2025019815A3 (en) Enhanced delivery epinephrine and prodrug compositions
WO2024254411A3 (en) Substituted benzofuran propyl amine modulators of monoaminergic transporters
PE20200699A1 (en) SYNERGIC COMPOSITIONS INCLUDING DIMIRACETAM (R) (1) AND DIMIRACETAM (S) (2) IN A NON-RACEMIC PROPORTION
WO2020159159A3 (en) Pharmaceutical composition for prevention or treatment of lysosomal storage disorders
WO2024254505A3 (en) Compositions and methods for increasing exposure of r(-)-mda
WO2024044778A3 (en) Novel modulators of fshr and uses thereof
WO2024086246A3 (en) 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
WO2024259100A3 (en) Piperidine inhibitor of slc6a19 function

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24836562

Country of ref document: EP

Kind code of ref document: A2